1-(4-溴丁氧基)-4-甲苯 | 3257-49-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(4-溴丁氧基)-4-甲苯
• 英文名称: 1-bromo-4-(4-methylphenoxy)butane
• 英文别名: 1-(4-bromobutoxy)-4-methylbenzene
• CAS: 3257-49-6
• 化学式: C₁₁H₁₅BrO
• 分子量: 243.143
• InChiKey: WKFSNKTYOQGTBN-UHFFFAOYSA-N

物化性质

• 熔点：
  40 °C
• 沸点：
  148-151.5 °C (10 mmHg)
• 密度：
  1.263±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  避免与不相容的材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S37/39
• 危险类别码：
  R20/22,R36/37/38
• 海关编码：
  2909309090
• 储存条件：
  密封保存，应储存在阴凉干燥的仓库中。

SDS

Name:	1-(4-Bromobutoxy)-4-methylbenzene 95% Material Safety Data Sheet
Synonym:
CAS:	3257-49-6

Section 1 - Chemical Product MSDS Name:1-(4-Bromobutoxy)-4-methylbenzene 95% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3257-49-6	1-(4-Bromobutoxy)-4-methylbenzene	95%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3257-49-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: white
Odor: stench
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 148 - 151.5 deg C @10mmHg
Freezing/Melting Point: 40 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: >150 deg C
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H15BrO
Molecular Weight: 243.14

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3257-49-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4-Bromobutoxy)-4-methylbenzene - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 3257-49-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3257-49-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3257-49-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-溴丁氧基)-4-甲苯 在 N-碘代丁二酰亚胺 、 sodium hydride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 1.0h， 生成 1-(4-(4-iodo-3-methoxy-3-methylbutoxy)butoxy)-4-methylbenzene
  参考文献：
  名称：

  在α甲氧基γ-烷氧基烷基碘化物基板的具有超级电子给体从4-DMAP和得到的反应中观察到的分片Ñ -methylbenzimidazole †往最‡ §

  摘要：

  衍生自的超电子给体（SED）的反应 4-二甲基氨基吡啶 和从 N-甲基苯并咪唑与α-甲氧基-γ-烷氧基烷基碘一起使用会导致γ-烷氧基作为其醇的释放。这与从烷基卤化物前体产生烷基自由基，以及通过SED的自由基阳离子捕获这些自由基，然后进行杂化裂解相一致。

  DOI：

  10.1039/c0ob01282c
• 作为产物：
  描述：

  对甲酚 在 silver(I) bromide 、 三甲基溴硅烷 、 偶氮二甲酸二异丙酯 、 氧气 、 三苯基膦 、 1,5-环辛二烯 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 生成 1-(4-溴丁氧基)-4-甲苯
  参考文献：
  名称：

  铁（II）和铜（I）控制烯烃氢溴化反应的总区域选择性

  摘要：

  描述了一种可以完全控制烯烃氢溴化反应的区域选择性的新方法。在此，我们报告了一种使用 TMSBr 和氧作为常用试剂的自由基过程，其中在存在百万分之几的 Cu(I) 物种的情况下，反马尔可夫尼科夫产物的形成发生，而马尔可夫尼科夫产物的形成发生在存在 30 mol% 的溴化铁 (II)。密度泛函理论计算结合福井的激进磁化率支持获得的结果。

  DOI：

  10.1021/acs.orglett.1c02186

文献信息

• The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH
  作者：Li-Yan Zeng、Fubiao Yang、Kaixuan Chen、Yunong Zeng、Zhenzhou Jiang、Shuwen Liu、Baomin Xi

  DOI：10.1016/j.ejmech.2020.112616

  日期：2020.11

  H-indol-3-yl)butanoic acid 4aaa was designed against BPH and synthesized by two steps of N-alkylation. One-pot protocol towards 4aaa was newly developed. With IL [C6min]Br as solvent, the yield of 4aaa was increased to 75.1 % from 16.0 % and the reaction time was shortened in 1.5 hours from 48 hours. 25 Derivatives structurally based on arylpiperazine and indolyl butyric acid with alkyl linker were

  基于两种α的SAR 1 -AR拮抗剂和5α还原酶（5AR）抑制剂，双重作用的药剂4-（1-（4-（4-（2-甲氧基苯基）哌嗪-1-基）丁基针对BPH设计了）-1 H-吲哚-3-基）丁酸4aaa，并通过N-烷基化的两个步骤合成。新开发了针对4aaa的一锅协议。用IL [C 6分钟]溴作为溶剂，收率4AAA从16.0％提高到75.1％，反应时间是1.5小时缩短为48小时。制备了25种基于芳基哌嗪和吲哚基丁酸的具有烷基连接基的衍生物。进一步扩展了该协议，以获取另外14个衍生词，其中O-烷基化参与其中，并应用于生物有效分子DPQ和阿立哌唑的合成。预期地，化合物4AAA表现出α的双重抑制1 -AR和5α还原酶，和exihited针对人类细胞没有明显的细胞毒性。还确定了4aaa的药代动力学特性。
• Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids,
  申请人：Byk Gulden Lomberg Chemische Fabrik GmbH

  公开号：US04337267A1

  公开（公告）日：1982-06-29

  Phenalkoxyalky- and phenoxyalkyl-substituted oxiranecarboxylic acids of the formula ##STR1## wherein R.sup.1 denotes a hydrogen atom (--H), a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group or a trifluoromethyl group, R.sup.2 has one of the meanings of R.sup.1, R.sup.3 denotes a hydrogen atom (--H) or a lower alkyl group, Y denotes --O--(CH.sub.2).sub.m --, m denotes O or an integer from 1 to 4, and n denotes an integer from 2 to 8, with the proviso that the sum of m and n is an integer from 2 to 8, and the salts of the acids are new compounds. They display a hypoglycaemic action in warm-blooded animals. Processes for the preparation of the new compounds and of the intermediate products required for their preparation are described.

  Phenalkoxyalky-和phenoxyalkyl-取代的环氧丙烯酸的化学式为##STR1##其中R.sup.1代表氢原子(--H)、卤素原子、低烷基、低烷氧基、硝基或三氟甲基，R.sup.2具有R.sup.1的含义之一，R.sup.3代表氢原子(--H)或低烷基，Y代表--O--(CH.sub.2).sub.m --，m代表O或1到4之间的整数，n代表2到8之间的整数，但m和n的总和为2到8之间的整数，这些酸的盐是新化合物。它们在温血动物中显示降糖作用。描述了制备新化合物和制备所需的中间产物的过程。
• Design of PAP-1, a Selective Small Molecule Kv1.3 Blocker, for the Suppression of Effector Memory T Cells in Autoimmune Diseases
  作者：Alexander Schmitz、Ananthakrishnan Sankaranarayanan、Philippe Azam、Kristina Schmidt-Lassen、Daniel Homerick、Wolfram Hänsel、Heike Wulff

  DOI：10.1124/mol.105.015669

  日期：2005.11

  The lymphocyte K+ channel Kv1.3 constitutes an attractive pharmacological target for the selective suppression of terminally differentiated effector memory T (TEM) cells in T cell-mediated autoimmune diseases, such as multiple sclerosis and type 1 diabetes. Unfortunately, none of the existing small-molecule Kv1.3 blockers is selective, and many of them, such as correolide, 4-phenyl-4-[3-(methoxyphenyl)-3-oxo-2-azapropyl]cyclohexanone, and our own compound Psora-4 inhibit the cardiac K+ channel Kv1.5. By further exploring the structure-activity relationship around Psora-4 through a combination of traditional medicinal chemistry and whole-cell patch-clamp, we identified a series of new phenoxyalkoxypsoralens that exhibit 2- to 50-fold selectivity for Kv1.3 over Kv1.5, depending on their exact substitution pattern. The most potent and “drug-like” compound of this series, 5-(4-phenoxybutoxy)psoralen (PAP-1), blocks Kv1.3 in a use-dependent manner, with a Hill coefficient of 2 and an EC50 of 2 nM, by preferentially binding to the C-type inactivated state of the channel. PAP-1 is 23-fold selective over Kv1.5, 33- to 125-fold selective over other Kv1-family channels, and 500- to 7500-fold selective over Kv2.1, Kv3.1, Kv3.2, Kv4.2, HERG, calcium-activated K+ channels, Na+,Ca2+, and Cl- channels. PAP-1 does not exhibit cytotoxic or phototoxic effects, is negative in the Ames test, and affects cytochrome P450-dependent enzymes only at micromolar concentrations. PAP-1 potently inhibits the proliferation of human TEM cells and suppresses delayed type hypersensitivity, a TEM cell-mediated reaction, in rats. PAP-1 and several of its derivatives therefore constitute excellent new tools to further explore Kv1.3 as a target for immunosuppression and could potentially be developed into orally available immunomodulators.

  淋巴细胞K+通道Kv1.3是选择性抑制T细胞介导的自身免疫性疾病（如多发性硬化症和1型糖尿病）中终末分化效应记忆T（TEM）细胞的有吸引力的药理学靶点。不幸的是，目前存在的所有小分子Kv1.3阻断剂均不具备选择性，其中许多如柯里奥利德、4-苯基-4-[3-(甲氧苯基)-3-酮-2-氮杂丙基]环己酮以及我们自己的化合物Psora-4均可抑制心脏K+通道Kv1.5。通过结合传统药物化学和全细胞膜片钳技术进一步探索Psora-4的构效关系，我们鉴定了一系列新的苯氧烷氧基补骨脂素，它们对Kv1.3的选择性比Kv1.5高2至50倍，具体取决于其取代模式。这一系列化合物中，最具有强效和“类药物”性质的化合物为5-(4-苯氧基丁氧基)补骨脂素（PAP-1），它以使用依赖性方式阻断Kv1.3，Hill系数为2，EC50为2 nM，通过优先结合通道的C型失活态。PAP-1对Kv1.5的选择性为23倍，对其他Kv1家族通道的选择性为33至125倍，对Kv2.1、Kv3.1、Kv3.2、Kv4.2、HERG、钙激活K+通道、Na+、Ca2+及Cl-通道的选择性为500至7000倍。PAP-1无细胞毒性或光毒性，Ames试验呈阴性，对细胞色素P450依赖性酶的影响仅在微摩尔浓度下显现。PAP-1能强效抑制人TEM细胞的增殖并抑制大鼠中的迟发型超敏反应（一种TEM细胞介导的反应）。因此，PAP-1及其若干衍生物构成了探索Kv1.3作为免疫抑制靶点的新工具，并有可能开发成口服可用的免疫调节剂。
• Efficacy of novel phenoxyalkyl pyridinium oximes as brain-penetrating reactivators of cholinesterase inhibited by surrogates of sarin and VX
  作者：Janice E. Chambers、Howard W. Chambers、Kristen E. Funck、Edward C. Meek、Ronald B. Pringle、Matthew K. Ross

  DOI：10.1016/j.cbi.2016.07.004

  日期：2016.11

  behavior with several of the more effective novel oximes, but not 2-PAM. Therefore these novel oximes have demonstrated an ability to reactivate inhibited ChE in brain preparations from two species and in vivo data support their ability to enter the brain and provide a therapeutic action. These novel oximes have the potential to be developed into improved antidotes for nerve agent therapy.

  吡啶鎓肟是强亲核试剂，许多是有机磷酸酶抑制胆碱酯酶（ChE）的有效活化剂。然而，当前的肟再活化剂在穿越血脑屏障和再活化完整生物中的脑ChE方面是无效的。我们的实验室已经开发了一系列取代的苯氧基烷基吡啶鎓肟（美国专利9,227,937 B2），目的是鉴定能有效跨越血脑屏障的活化剂。发现该系列的前35个在体外具有相似的特征沙林替代品（邻苯二甲酰亚胺基异丙基甲基膦酸酯，PIMP）或VX替代品（硝基苯基乙基甲基膦酸酯，NEMP）在牛脑制剂中抑制ChE活化剂的功效，如先前在大鼠脑制剂中观察到的。这些新型肟中的许多已经显示出能够降低用高致死剂量的沙林替代品（硝基苯基异丙基甲基膦酸酯，NIMP）或VX替代NEMP处理的大鼠大脑中ChE抑制水平的能力。肟给药后2小时的再活化水平高达35％，而目前批准的治疗药物2-PAM并未降低脑ChE抑制作用。另外，有证据显示几种更有效的新型肟可减轻癫痫样行为，但2-PA
• Effect of Chromophore-Charge Distance on the Energy Transfer Properties of Water-Soluble Conjugated Oligomers
  作者：Bin Liu、Brent S. Gaylord、Shu Wang、Guillermo C. Bazan

  DOI：10.1021/ja028961w

  日期：2003.6.1

  The synthesis of 1,4-bis(9,9'-bis(3"-(N,N,N-trimethylammonium)-propyl)-2'-fluorenyl)benzene tetrabromide (C3), 1,4-bis(9,9'-bis(4"-(N,N,N-trimethylammonium)-butyl)-2'-fluorenyl)benzene tetrabromide (C4), 1,4-bis(9,9'-bis(6"-(N,N,N-trimethylammonium)-hexyl)-2'-fluorenyl)benzene tetrabromide (C6), and 1,4-bis(9,9'-bis(8"-(N,N,N-trimethylammonium)-octyl)-2'-fluorenyl)benzene tetrabromide (C8) is reported

  1,4-双(9,9'-双(3"-(N,N,N-三甲基铵)-丙基)-2'-芴基)苯四溴化物(C3)、1,4-双(9)的合成,9'-双(4"-(N,N,N-三甲基铵)-丁基)-2'-芴基)苯四溴化物 (C4), 1,4-双(9,9'-双(6"-) N,N,N-三甲基铵)-己基)-2'-芴基)苯四溴化物(C6)和1,4-双(9,9'-双(8"-(N,N,N-三甲基铵)-报道了辛基)-2'-芴基)苯四溴化物(C8)。C3-C8 和受体五钠 1,4-bis(4'(2",4"-bis(butoxysulfonate)-styryl)styyl)-2-(butoxysulfonate)-5-甲氧基苯 (3) 之间的荧光能量转移实验，荧光素标记的单链 DNA 和荧光素标记的双链 DNA 在水中、缓冲液、和甲醇揭示了疏水力和静电力在确定发色团-发色团紧密接近度方面的重要性。在水中，具有较长侧链长度的低聚物显示出更好的能量转移，以及更高的

表征谱图